JTO Clinical and Research Reports最新文献

{"title":"Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter Study","authors":"Akito Miyazaki MD ,&nbsp;Kinnosuke Matsumoto MD ,&nbsp;Motohiro Tamiya MD ,&nbsp;Kiyohide Komuta MD ,&nbsp;Kensuke Kanaoka MD ,&nbsp;Tomoki Kuge MD ,&nbsp;Takayuki Shiroyama MD, PhD ,&nbsp;Akihiro Tsukaguchi MD ,&nbsp;Akihiro Tamiya MD ,&nbsp;Keijiro Yamauchi MD, PhD ,&nbsp;Hidekazu Suzuki MD ,&nbsp;Yasuhiro Mihashi MD ,&nbsp;Masahide Mori MD, PhD ,&nbsp;Koki Moritomo MD ,&nbsp;Yuhei Kinehara MD, PhD ,&nbsp;Midori Yoneda MD ,&nbsp;Osamu Morimura MD, PhD ,&nbsp;Kouji Azuma MD ,&nbsp;Satoshi Tanaka MD ,&nbsp;Toshie Niki MD, PhD ,&nbsp;Atsushi Kumanogoh MD, PhD","doi":"10.1016/j.jtocrr.2026.100953","DOIUrl":"10.1016/j.jtocrr.2026.100953","url":null,"abstract":"<div><h3>Introduction</h3><div>This study aimed to evaluate the real-world clinical outcomes of pembrolizumab monotherapy in patients with advanced NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) of 1% to 49%.</div></div><div><h3>Methods</h3><div>A multicenter retrospective analysis was conducted for outcomes of 114 patients with stages II to IV or recurrent NSCLC and PD-L1 TPS of 1% to 49%, who received first-line pembrolizumab monotherapy.</div></div><div><h3>Results</h3><div>The median progression-free survival (PFS) was 5.6 months, with 6-month and 60-month PFS rates of 47.4% and 5.1%, respectively. The median overall survival (OS) was 15.8 months, with 24-month and 60-month OS rates of 34.8% and 17.0%, respectively. The objective response rate was 36.9%, and the disease control rate was 60.4%. Multivariate analysis identified liver metastasis as a significant negative prognostic factor for PFS, but a high neutrophil-to-lymphocyte ratio (NLR) revealed a trend toward worse PFS. Similarly, liver metastasis, high NLR, and poor performance status were significantly associated with worse OS. Grade more than or equal to 3 immune-related adverse events were observed in 20.2% of patients, with pneumonitis being the most common. Those with a history of interstitial lung disease had a higher incidence of severe pneumonitis than those without. Treatment discontinuation due to disease progression occurred in 65.8% of patients, whereas 23.7% discontinued due to adverse events.</div></div><div><h3>Conclusions</h3><div>First-line pembrolizumab monotherapy demonstrated moderate efficacy and acceptable safety in patients with advanced NSCLC with PD-L1 TPS of 1% to 49%. Liver metastasis, high NLR, and poor performance status were identified as prognostic factors.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 4","pages":"Article 100953"},"PeriodicalIF":3.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147388196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant Larotrectinib in a Resected Secretory Carcinoma-Like Lung Adenocarcinoma Harboring EML4-NTRK3 Fusion: Case Report","authors":"Vladmir Cláudio Cordeiro de Lima MD, PhD ,&nbsp;Breno Jeha Araújo MD ,&nbsp;Felipe D' Almeida Costa MD, PhD ,&nbsp;Beatriz Fuga Rossi Teixeira MD ,&nbsp;André Luiz Cicilini MD ,&nbsp;Carolina de Bustamante Fernandes PhD ,&nbsp;Juliana Folador Morellato MD, MsC ,&nbsp;Rodrigo Dienstmann MD, MBA ,&nbsp;Mariana Tosello Laloni MD, PhD","doi":"10.1016/j.jtocrr.2025.100946","DOIUrl":"10.1016/j.jtocrr.2025.100946","url":null,"abstract":"<div><div>Secretory carcinoma of the lung is an exceptionally rare salivary gland-type malignancy, typically associated with NTRK fusions. We report a 71-year-old woman with pulmonary stage IIIA adenocarcinoma having salivary gland differentiation and solid-cribriform architecture, confirmed by S100 and Pan-TRK immunohistochemistry. Broad DNA and RNA next-generation sequencing identified an <em>EML4-NTRK3</em> fusion. After adjuvant chemotherapy, maintenance larotrectinib was initiated based on proven TRK inhibitor efficacy in metastatic NTRK-fusion tumors and emerging evidence for targeted therapy benefit in driver-positive early stage lung adenocarcinoma. Our findings demonstrate the value of molecular pathology in the diagnostic journey of pulmonary malignancies, guiding rare fusion detection and supporting therapeutic decisions based on rare fusions in early stage disease.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 3","pages":"Article 100946"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147307311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential Immune Microenvironment Biomarkers in SCLC: J-TAIL-2 Observational Study","authors":"Masayuki Shirasawa MD, PhD ,&nbsp;Makoto Nishio MD, PhD ,&nbsp;Kadoaki Ohashi MD, PhD ,&nbsp;Atsushi Osoegawa MD, PhD ,&nbsp;Eiki Kikuchi MD, PhD ,&nbsp;Hideharu Kimura MD, PhD ,&nbsp;Yasushi Goto MD, PhD ,&nbsp;Junichi Shimizu MD, PhD ,&nbsp;Eisaku Miyauchi MD, PhD ,&nbsp;Hiroshige Yoshioka MD, PhD ,&nbsp;Ichiro Yoshino MD, PhD ,&nbsp;Toshihiro Misumi PhD ,&nbsp;Yasushi Yatabe MD, PhD ,&nbsp;Tatsuya Yoshida MD, PhD ,&nbsp;Jumpei Kashima MD, PhD ,&nbsp;Masahide Oki MD, PhD ,&nbsp;Hisao Ashimura MS ,&nbsp;Yuki Kobayashi MS ,&nbsp;Misa Tanaka MS ,&nbsp;Akihiko Gemma MD, PhD","doi":"10.1016/j.jtocrr.2025.100926","DOIUrl":"10.1016/j.jtocrr.2025.100926","url":null,"abstract":"<div><h3>Introduction</h3><div>Effective predictors of response to atezolizumab plus carboplatin/etoposide (CE) therapy in extensive-stage SCLC (ES-SCLC) remain limited. This exploratory analysis from J-TAIL-2 aimed to identify markers of survival benefit with atezolizumab plus CE therapy in ES-SCLC.</div></div><div><h3>Methods</h3><div>J-TAIL-2 (<span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> ID, <span><span>NCT04501497</span><svg><path></path></svg></span>) was a multicenter observational study that enrolled patients receiving atezolizumab plus CE (ES-SCLC cohort) in clinical practice in Japan per local label and treatment guidelines. In this exploratory analysis, the association of CD8+ tumor-infiltrating lymphocyte (TIL) density and SCLC subtypes (SCLC-A [ASCL1 dominant], SCLC-N [NEUROD1 dominant], SCLC-P [ASCL1/NEUROD1 double-negative with POU2F3 expression], and SCLC-O [ASCL1/NEUROD1 double-negative not otherwise specified]) with overall survival (OS) and progression-free survival (PFS) was evaluated. SCLC subtyping was performed by immunohistochemistry.</div></div><div><h3>Results</h3><div>SCLC samples (n = 100; data cutoff, February 3, 2023) were categorized as SCLC-A (73%), SCLC-N (16%), SCLC-P (8%), and SCLC-O (3%). Among 96 patients who received first-line atezolizumab plus CE, median age was 72 (range, 39–87) years and 81% were male. Furthermore, 56 patients were classified into the CD8+ TIL-high subgroup and 40 into the TIL-low subgroup. Median (m)PFS with atezolizumab plus CE was 6.1 months (95% confidence interval [CI]: 4.5–7.5) in the TIL-high versus 4.4 months (95% CI: 4.0–5.1) in the TIL-low subgroup (<em>p</em> = 0.01); mOS was 18.4 (95% CI: 11.8–not estimable) versus 10.8 months (95% CI: 7.7–16.2; <em>p</em> = 0.04). mOS and mPFS were not significantly different between SCLC subtypes but were numerically shorter in the SCLC-N group.</div></div><div><h3>Conclusions</h3><div>CD8+ TIL density is a potential biomarker of clinical benefit in ES-SCLC and may facilitate patient selection for atezolizumab combination therapy.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 3","pages":"Article 100926"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147355479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Patterns in Early Stage NSCLC in Asia: Findings From the ELEVATE Study","authors":"Myung-Ju Ahn MD, PhD ,&nbsp;Daniel SW. Tan BSc, M.B.B.S., MRCP, PhD ,&nbsp;Morgan Windsor FRACS ,&nbsp;Boon-Hean Ong M.B.B.S., FRCSEd (CTh) ,&nbsp;James Chung-Man Ho MD ,&nbsp;Hong Kwan Kim MD, PhD ,&nbsp;Victor Ho-Fun Lee MD ,&nbsp;Feng-Ming Hsu MD, PhD ,&nbsp;Jin Yuan Shih MD, PhD ,&nbsp;Duc Nhat Minh Pham MD ,&nbsp;Cam Phuong Pham MD, PhD ,&nbsp;Sharon Chua PhD ,&nbsp;See-Hwee Yeo PhD ,&nbsp;Ivy de Dios MD","doi":"10.1016/j.jtocrr.2025.100945","DOIUrl":"10.1016/j.jtocrr.2025.100945","url":null,"abstract":"<div><h3>Introduction</h3><div>The management of early stage NSCLC is evolving with new therapies. Given the lack of guidelines for Asia Pacific, understanding the different factors affecting treatment decisions is key to effective clinical practice. This cross-sectional study describes management patterns for early stage NSCLC in six territories across the region and identifies factors influencing treatment choices.</div></div><div><h3>Methods</h3><div>From June 2022 to July 2023, we recruited lung cancer specialists from public and private health care systems in Australia, Hong Kong, South Korea, Singapore, Taiwan, and Vietnam to complete a survey on treatment considerations in early stage NSCLC among three patient groups based on American Joint Committee on Cancer disease staging.</div></div><div><h3>Results</h3><div>Among 505 physicians screened, 212 were eligible for our study. They frequently screened high-risk individuals. Biomarker testing was common as part of diagnosis and at disease recurrence. Surgery followed by adjuvant chemotherapy, definitive concurrent chemoradiation, and definitive chemoradiation followed by immunotherapy were mostly recommended, depending on disease stage and presence of oncogenic alteration. Variations were observed among territories and specialties. Cisplatin was preferred over carboplatin for both neoadjuvant and adjuvant therapies. Physicians were more likely to prescribe neoadjuvant or adjuvant treatments for patients with lower Eastern Cooperative Oncology Group performance status and/or higher nodal stage.</div></div><div><h3>Conclusions</h3><div>This study revealed that management of early stage NSCLC across Asia Pacific largely follows international guidelines at the time of survey; however, variations exist. Our findings provide useful insights into real-world management patterns in the region and will be valuable in helping clinicians make informed management decisions.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 3","pages":"Article 100945"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146193057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MET-Driven Resistance to Sotorasib in KRAS G12C–Mutant NSCLC and Response to Combined KRAS and MET Inhibition","authors":"Richard Riedel MD ,&nbsp;Lea Ruge MD ,&nbsp;Malte Verheyen MD ,&nbsp;Felix John MD ,&nbsp;Heather Scharpenseel MD ,&nbsp;Lucia Nogova MD, PhD ,&nbsp;Sebastian Michels MD ,&nbsp;Rieke N. Fischer MD ,&nbsp;Anna Eisert MD ,&nbsp;Carolin Jakob MD ,&nbsp;Emanuel Niesen MD ,&nbsp;Jana Fassunke MD ,&nbsp;Janna Siemanowski-Hrach MD ,&nbsp;Carina Heydt MD ,&nbsp;Anne Bunck MD ,&nbsp;Udo Siebolts MD, PhD ,&nbsp;Sabine Merkelbach-Bruse MD, PhD ,&nbsp;Reinhard Buettner MD, PhD ,&nbsp;Jürgen Wolf MD, PhD ,&nbsp;Matthias Scheffler MD, PhD","doi":"10.1016/j.jtocrr.2025.100925","DOIUrl":"10.1016/j.jtocrr.2025.100925","url":null,"abstract":"<div><h3>Introduction</h3><div><em>KRAS G12C</em> mutations define a molecularly distinct subset of NSCLC for which targeted therapy with sotorasib has exhibited clinical efficacy. However, acquired resistance is inevitable. <em>MET</em> amplification has been described as a putative off-target resistance mechanism, although its clinical relevance remains incompletely understood.</div></div><div><h3>Methods</h3><div>We conducted a retrospective case series of patients with <em>KRAS G12C</em>–mutant NSCLC treated with sotorasib at the University Hospital Cologne, Germany. Patients with available paired pre- and posttreatment biopsies were analyzed for resistance mechanisms using routine molecular diagnostics, including <em>MET</em> fluorescence in situ hybridization.</div></div><div><h3>Results</h3><div>Nine patients with paired pre and posttreatment biopsies were identified. High-level <em>MET</em> amplification was detected by fluorescence in situ hybridization in four cases and intermediate-level amplification in one case after progression on sotorasib. Notably, one patient with acquired <em>MET</em> amplification achieved a renewed partial response to the combination of sotorasib and tepotinib after progression on sotorasib monotherapy.</div></div><div><h3>Conclusion</h3><div>This study provides real-world evidence that <em>MET</em> amplification is an acquired and potentially targetable resistance mechanism to KRAS G12C inhibition in NSCLC. Our findings support rebiopsy at progression on sotorasib. Further prospective trials are warranted to validate <em>MET</em> amplification as a resistance mechanism and to define optimal therapeutic thresholds for combined KRAS and MET inhibition.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 3","pages":"Article 100925"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147402930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acquired ERBB2 Amplification and Overexpression as On-Target Resistance Mechanisms to Zongertinib With Subsequent Response to Trastuzumab-Deruxtecan: A Case Report","authors":"David John McMahon MD ,&nbsp;Alexius John MD ,&nbsp;Foteini Kalofonou PhD ,&nbsp;Nawa Amin PhD ,&nbsp;Sarah Sarker ,&nbsp;Joanna Vick ,&nbsp;Nadia Yousaf MD ,&nbsp;Nadza Tokaca MD ,&nbsp;JanLukas Robertus PhD ,&nbsp;Suzanne MacMahon PhD ,&nbsp;Sanjay Popat FRCP, PhD","doi":"10.1016/j.jtocrr.2026.100960","DOIUrl":"10.1016/j.jtocrr.2026.100960","url":null,"abstract":"<div><div>A number of drugs are in development for the treatment of <em>ERBB2</em>(<em>HER2</em>)-mutated NSCLC, including antibody-drug conjugates such as trastuzumab-deruxtecan and tyrosine kinase inhibitors such as zongertinib and sevabertinib. Herein, we report a case of relapsed advanced <em>ERBB2</em>-mutant NSCLC with acquired resistance to zongertinib potentially mediated through <em>ERBB2</em> amplification and <em>HER2</em> 3+ immunohistochemistry overexpression with subsequent durable response to fifth-line trastuzumab-deruxtecan. We propose this as a mechanism for zongertinib resistance, one that may underpin a biological rationale for future <em>ERBB2</em> tyrosine kinase inhibitor–antibody-drug conjugate combination therapy.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 3","pages":"Article 100960"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ALK Inhibitor Response in Novel ZFPM2::ALK and TRIM24::ALK Fusion-Positive Lung Cancers: Case Report","authors":"Charles Hsu MD,&nbsp;Mohamed Yakoub MD, PhD,&nbsp;Michael Offin MD,&nbsp;Juliana Eng MD,&nbsp;Alexander Drilon MD,&nbsp;Soo-Ryum Yang MD","doi":"10.1016/j.jtocrr.2025.100934","DOIUrl":"10.1016/j.jtocrr.2025.100934","url":null,"abstract":"<div><h3>Background</h3><div><em>ALK</em> fusion-positive NSCLC is driven by a range of fusion partners, most often <em>EML4::ALK</em>. The clinical impact, oncogenicity, and resistance mechanisms of rare, noncanonical <em>ALK</em> fusions remain underexplored. We describe two previously unreported <em>ALK</em> fusion partners in NSCLC and explore the potential mechanisms of resistance in each case, including on-target and bypass mutations, as well as the use of next-generation sequencing (NGS) testing on cerebrospinal fluid (CSF) as a useful tool.</div></div><div><h3>Case Presentation</h3><div>We report two patients with metastatic NSCLC harboring novel <em>ZFPM2::ALK</em> and <em>TRIM24::ALK</em> fusions. Both patients achieved marked partial responses to first-line alectinib, confirming the oncogenic and actionable nature of the fusions. The patient with <em>ZFPM2::ALK</em> fusion developed leptomeningeal disease after 27 months; CSF NGS revealed persistent fusion and newly acquired <em>CDKN2A/B</em> deletion. The patient with <em>TRIM24::ALK</em> fusion, following durable responses to alectinib and lorlatinib, relapsed with detection of on-target <em>ALK</em> kinase domain mutations (F1174V, I1171N) and <em>MYC</em> amplification on progression.</div></div><div><h3>Conclusions</h3><div>These cases expand the landscape of noncanonical <em>ALK</em> fusions in NSCLC which are responsive to approved ALK TKIs and offer insights into oncogenic and resistance mechanisms. Comprehensive molecular workup, including RNA-based NGS, is essential for detecting rare but actionable ALK rearrangements and optimizing therapeutic strategy. NGS of CSF was a valuable tool for the detection of clinically suspected leptomeningeal disease and disease monitoring.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 3","pages":"Article 100934"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146193069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of a Rare Intra-ALK Inversion and ALK Rearrangement in a Lung Adenocarcinoma Patient by FoundationOne Liquid CDx and Successful Treatment with Alectinib: Case Report","authors":"Chiaki Kanno MD, PhD,&nbsp;Satoshi Takahashi MD, PhD,&nbsp;Masaru Hagiwara MD, PhD,&nbsp;Hideyuki Furumoto MD, PhD,&nbsp;Yujin Kudo MD, PhD,&nbsp;Yoshihisa Shimada MD, PhD,&nbsp;Masatoshi Kakihana MD, PhD,&nbsp;Tatsuo Ohira MD, PhD,&nbsp;Norihiko Ikeda MD, PhD","doi":"10.1016/j.jtocrr.2026.100956","DOIUrl":"10.1016/j.jtocrr.2026.100956","url":null,"abstract":"<div><div>A 50-year-old woman with stage IVB lung adenocarcinoma tested negative for driver mutations using the Oncomine Dx Target Test Multi-CDx system (Thermo Fisher Scientific, Waltham, MA). After undergoing chemotherapy and immunotherapy, FoundationOne Liquid CDx (Foundation Medicine, Inc., Cambridge, MA) identified a rare <em>EML4</em>-<em>ALK</em> gene rearrangement. Treatment with alectinib led to rapid clinical improvement and sustained disease control for more than 7 months. This case highlights the value of next-generation sequencing-based profiling in detecting rare actionable alterations missed by standard tests. We also include a discussion on why the <em>EML4-AKL</em> fusion was not detected in the usual test.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 3","pages":"Article 100956"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146193070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune Doublet Checkpoint Inhibition in EGFR-Mutated NSCLC: A Fire That Fails to Illuminate the Orchard","authors":"Richard Pham MBBS ,&nbsp;Surein Arulananda MBBS, PhD","doi":"10.1016/j.jtocrr.2026.100957","DOIUrl":"10.1016/j.jtocrr.2026.100957","url":null,"abstract":"","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 3","pages":"Article 100957"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146192422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Calling With One Voice—Alignment of Strategy for Lung Cancer in Patients of African Descent","authors":"Emily Stone M.B.B.S., PhD, FRACP","doi":"10.1016/j.jtocrr.2025.100902","DOIUrl":"10.1016/j.jtocrr.2025.100902","url":null,"abstract":"","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 3","pages":"Article 100902"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147402929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}